2024 A Focus on Pathology

aci-pathology-cancers_-_Edited.png

tuesday, Dec. 10, 2024 | 11 A.m.–3 P.M. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of the clinical implementation of immuno-oncology pathology. FREE for healthcare professionals, students, patients and patient advocates.

The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Janis M. Taube, MD, MSc
 Johns Hopkins University School of Medicine

Julie Stein Deutsch

Julie Stein Deutsch, MD
Johns Hopkins University School of Medicine

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Tuesday, Dec. 10, 2024 at 11 a.m-3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Pathology >

Program Agenda

11–11:05 a.m.

 

Welcome and Introduction

11:05–11:35 a.m.

  

Introduction to Pathology Biomarkers for Precision Oncology: Clinical Trials and
Clinical Implementation
Tricia Cottrell, MD, PhD – Queen’s University

11:35 a.m.–
12:05 p.m.

 

Pathologic Response Assessment: Both Endpoint and Biomarker
Janis Taube, MD – Johns Hopkins University School of Medicine

12:05–12:35 p.m.

 

Pan-Cancer Scoring System for Pathologic Response: Overview and Steps to
Implementation
Julie Stein Deutsch, MD – Johns Hopkins University School of Medicine

12:35–12:50 p.m.

 

Questions and Discussions

12:50–1:05 p.m. 

 

Break

1:05–1:35 p.m.

 

Clinical Implementation of Multiplex Immunofluorescence (mIF) at a Single Academic Institution
Scott Rodig, MD, PhD – Brigham and Women’s Hospital and The Dana-Farber Cancer
Institute

1:35–2:05 p.m.

 

Raising the Bar for mIF Data: The SITC mIF/IHC Guidelines
Joe Yeong, MBBS, PhD, FRCPath(UK) – Singapore General Hospital

2:05–2:35 p.m.

 

Biomarker-Driven Oncology Clinical Trial Design
Chen Hu, PhD – Johns Hopkins University School of Medicine

2:35–2:50 p.m.

 

Questions and Discussions

2:50–3 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.


Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Discuss predictive markers in clinical use with cancer immunotherapies and their relevance to cancer immunotherapy approaches.
  • Summarize recent updates in newly approved FDA immunotherapies and their impact on diagnostics.

  • Describe the importance of pathologic response evaluation and its correlation with outcomes, specifically in the neoadjuvant setting.

  • Implement spatial biology-based approaches, such as multiplex fluorescence to assess immuno-oncological markers and patient response.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

 

Disclosures

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

SITC's Clinical Practice Guideline (CPG) Resources

Find information regarding disease-specific treatment algorithms and recommended administration of FDA-approved cancer immunotherapies. The guidelines are reviewed by expert panels on a recurring basis to account for newly available clinical trial data and FDA approvals.

 Relevant Guidelines

 Mini-Modules

 Featured Webinars